CPSE:BAVABiotechs
Bavarian Nordic’s BARDA Deal Reshapes JYNNEOS Stockpile And 2026 Outlook
Bavarian Nordic (CPSE:BAVA) received a major contract extension from the US government’s BARDA for its JYNNEOS smallpox vaccine.
The extension secures remaining JYNNEOS doses and includes an additional US$97 million commitment for further vaccine supply.
The agreement supports a shift to a freeze dried formulation designed for longer shelf life and stockpile use.
The company has updated its 2026 revenue and business guidance following the new BARDA commitments.
For investors looking at...